title: Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity.
abstract: We previously established that at 3 years postseroconversion, ~30% of HIV-infected individuals have cross-reactive neutralizing activity (CrNA) in their sera. Here we studied the kinetics with which CrNA develops and how these relate to the development of autologous neutralizing activity as well as viral escape and diversification. For this purpose, sera from five individuals with CrNA and one elite neutralizer that were obtained at three monthly intervals in the first year after seroconversion and at multiple intervals over the disease course were tested for neutralizing activity against an established multiclade panel of six viruses. The same serum samples, as well as sera from three individuals who lacked CrNA, were tested for their neutralizing activities against autologous clonal HIV-1 variants from multiple time points covering the disease course from seroconversion onward. The elite neutralizer already had CrNA at 9.8 months postseroconversion, in contrast with the findings for the other five patients, in whom CrNA was first detected at 20 to 35 months postseroconversion and peaked around 35 months postseroconversion. In all patients, CrNA coincided with neutralizing activity against autologous viruses that were isolated <12 months postseroconversion, while viruses from later time points had already escaped autologous neutralizing activity. Also, the peak in gp160 sequence diversity coincided with the peak of CrNA titers. Individuals who lacked CrNA had lower peak autologous neutralizing titers, viral escape, and sequence diversity than individuals with CrNA. A better understanding of the underlying factors that determine the presence of CrNA or even an elite neutralizer phenotype may aid in the design of an HIV-1 vaccine.
authors.affiliation: Department of Experimental Immunology, Sanquin Research, Landsteiner Laboratory, Center for Infection and Immunity Amsterdam, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
authors.forename: Zelda
authors.initials: Z
authors.lastname: Euler
authors.forename: Tom L G M
authors.initials: TL
authors.lastname: van den Kerkhof
authors.forename: Marit J
authors.initials: MJ
authors.lastname: van Gils
authors.forename: Judith A
authors.initials: JA
authors.lastname: Burger
authors.forename: Diana
authors.initials: D
authors.lastname: Edo-Matas
authors.forename: Pham
authors.initials: P
authors.lastname: Phung
authors.forename: Terri
authors.initials: T
authors.lastname: Wrin
authors.forename: Hanneke
authors.initials: H
authors.lastname: Schuitemaker
mesh_terms: D015331:Cohort Studies; D003429:Cross Reactions; D015483:HIV Antibodies / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology* / Q000821:virology; D015497:HIV-1 / Q000145:classification / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D009500:Neutralization Tests
chemical_list: D015483:HIV Antibodies